2024-515222-92-00
Recruiting
Phase 1
A study in healthy men to test how well different doses of BI 3776528 are tolerated
Boehringer Ingelheim International GmbH1 site in 1 country118 target enrollmentStarted: November 27, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 118
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A study in healthy men to test how well different doses of BI 3731579 are tolerated2023-510318-25-00Boehringer Ingelheim International GmbH64
Suspended
Phase 1
A study in healthy men to test how BI 1839100 is taken up and handled by the body2024-510870-26-00Boehringer Ingelheim International GmbH16
Completed
Phase 1
A study in healthy men to test how well different doses of BI 3802876 are tolerated2023-504538-23-00Boehringer Ingelheim International GmbH63
Completed
Not Applicable
A study in healthy men to test how well different doses of BI 1584862 are toleratedjRCT2071230088Nippon Boehringer Ingelheim Co., Ltd.32
Active, not recruiting
Not Applicable
A study in healthy men to test how well different doses of
BI 1819479 are toleratedjRCT2071220026Nippon Boehringer Ingelheim Co., Ltd.24